InMode Ltd. is rated a Strong Buy due to its robust balance sheet, proprietary technology, and international growth. Learn more about INMD stock here.

Good day, and welcome to the InMode fourth quarter and full year 2024 earnings results conference call. [Operator instructions] Please note, this event is being recorded. I would now like to turn the ...

Despite the quarterly beat, InMode’s stock declined after the company issued full-year 2026 guidance below Wall Street expectations. The company forecasts adjusted earnings of $1.43 to $1.48 per share ...

InMode’s products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share ...

YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results ...

InMode Ltd. (NASDAQ:INMD) reported fourth-quarter earnings and revenue on Tuesday that came in ahead of expectations, but its weaker-than-anticipated guidance for 2026 weighed on investor sentiment.

Good day, and welcome to InMode's second quarter 2024 earnings results conference call. All participants will be in listen-only mode. [Operator instructions]. After today's presentation, there will be ...